Search Results

There are 8126 results for: content related to: BRAF mutation-selective inhibition of thyroid cancer cells by the novel MEK inhibitor RDEA119 and genetic-potentiated synergism with the mTOR inhibitor temsirolimus

  1. Pharmacokinetic Profile of Temsirolimus With Concomitant Administration of Cytochrome P450-Inducing Medications

    The Journal of Clinical Pharmacology

    Volume 47, Issue 11, November 2007, Pages: 1430–1439, Joseph Boni, Cathie Leister, Jaime Burns, Maria Cincotta, Bruce Hug and Laurence Moore

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270007306957

  2. Temsirolimus targets multiple hallmarks of cancer to impede mesothelioma growth in vivo

    Respirology

    Volume 20, Issue 8, November 2015, Pages: 1263–1271, Maria Eleni Vazakidou, Sophia Magkouta, Charalampos Moschos, Ioannis Psallidas, Apostolos Pappas, Katherina Psarra and Ioannis Kalomenidis

    Version of Record online : 5 AUG 2015, DOI: 10.1111/resp.12604

  3. Population pharmacokinetics of temsirolimus and sirolimus in children with recurrent solid tumours: a report from the Children's Oncology Group

    British Journal of Clinical Pharmacology

    Volume 83, Issue 5, May 2017, Pages: 1097–1107, Tomoyuki Mizuno, Tsuyoshi Fukuda, Uwe Christians, John P. Perentesis, Maryam Fouladi and Alexander A. Vinks

    Version of Record online : 20 DEC 2016, DOI: 10.1111/bcp.13181

  4. You have full text access to this OnlineOpen article
    New developments in mammalian target of rapamycin inhibitors for the treatment of sarcoma

    Cancer

    Volume 118, Issue 6, 15 March 2012, Pages: 1486–1497, Mark Agulnik

    Version of Record online : 11 AUG 2011, DOI: 10.1002/cncr.26361

  5. You have free access to this content
    Targeting mTOR in renal cell carcinoma

    Cancer

    Volume 115, Issue S10, 15 May 2009, Pages: 2313–2320, Gary R. Hudes

    Version of Record online : 28 APR 2009, DOI: 10.1002/cncr.24239

  6. Immunotherapy for metastatic renal cell carcinoma

    Intervention Review

    The Cochrane Library

    Susanne Unverzagt, Ines Moldenhauer, Monika Nothacker, Dorothea Roßmeißl, Andreas V Hadjinicolaou, Frank Peinemann, Francesco Greco and Barbara Seliger

    Published Online : 15 MAY 2017, DOI: 10.1002/14651858.CD011673.pub2

  7. Targeted therapy for advanced renal cell carcinoma

    Intervention Review

    The Cochrane Library

    Chris Coppin, Lyly Le, Timothy J Wilt and Christian Kollmannsberger

    Published Online : 23 APR 2008, DOI: 10.1002/14651858.CD006017.pub2

  8. You have free access to this content
    Cost-Effectiveness of Temsirolimus for First Line Treatment of Advanced Renal Cell Carcinoma

    Value in Health

    Volume 13, Issue 1, January/February 2010, Pages: 61–68, Martin Hoyle, Colin Green, Jo Thompson-Coon, Zulian Liu, Karen Welch, Tiffany Moxham and Ken Stein

    Version of Record online : 25 SEP 2009, DOI: 10.1111/j.1524-4733.2009.00617.x

  9. You have full text access to this Open Access content
    Inhibition of mTOR by temsirolimus contributes to prolonged survival of mice with pleural dissemination of non-small-cell lung cancer cells

    Cancer Science

    Volume 102, Issue 7, July 2011, Pages: 1344–1349, Toshiaki Ohara, Munenori Takaoka, Shinichi Toyooka, Yasuko Tomono, Toshio Nishikawa, Yasuhiro Shirakawa, Tomoki Yamatsuji, Noriaki Tanaka, Toshiyoshi Fujiwara and Yoshio Naomoto

    Version of Record online : 2 JUN 2011, DOI: 10.1111/j.1349-7006.2011.01967.x

  10. Combined activity of temozolomide and the mTOR inhibitor temsirolimus in metastatic melanoma involves DKK1

    Experimental Dermatology

    Volume 26, Issue 7, July 2017, Pages: 598–606, Heike Niessner, Corinna Kosnopfel, Tobias Sinnberg, Daniela Beck, Kathrin Krieg, Ines Wanke, Konstantinos Lasithiotakis, Michael Bonin, Claus Garbe and Friedegund Meier

    Version of Record online : 12 JUL 2017, DOI: 10.1111/exd.13372

  11. You have free access to this content
    Targeted inhibition of mammalian target of rapamycin for the treatment of advanced renal cell carcinoma

    Cancer

    Volume 115, Issue 16, 15 August 2009, Pages: 3618–3630, Anil Kapoor and Robert A. Figlin

    Version of Record online : 28 MAY 2009, DOI: 10.1002/cncr.24409

  12. FDA Approval Summary: Temsirolimus as Treatment for Advanced Renal Cell Carcinoma

    The Oncologist

    Volume 15, Issue 4, April 2010, Pages: 428–435, Virginia E. Kwitkowski, Tatiana M. Prowell, Amna Ibrahim, Ann T. Farrell, Robert Justice, Shan Sun Mitchell, Rajeshwari Sridhara and Richard Pazdur

    Version of Record online : 23 MAR 2010, DOI: 10.1634/theoncologist.2009-0178

  13. You have free access to this content
    A phase 2 study of weekly temsirolimus and bortezomib for relapsed or refractory B-cell non-Hodgkin lymphoma: A Wisconsin Oncology Network study

    Cancer

    Volume 121, Issue 19, October 1, 2015, Pages: 3465–3471, Timothy S. Fenske, Namrata M. Shah, Kyung Mann Kim, Sandeep Saha, Chong Zhang, Arielle E. Baim, John P. Farnen, Adedayo A. Onitilo, Jules H. Blank, Harish Ahuja, Tim Wassenaar, Rubina Qamar, Patrick Mansky, Anne M. Traynor, Ryan J. Mattison and Brad S. Kahl

    Version of Record online : 16 JUN 2015, DOI: 10.1002/cncr.29502

  14. You have free access to this content
    Preclinical trial of a new dual mTOR inhibitor, MLN0128, using renal cell carcinoma tumorgrafts

    International Journal of Cancer

    Volume 134, Issue 10, 15 May 2014, Pages: 2322–2329, Alexandre Ingels, Hongjuan Zhao, Alan E. Thong, Matthias Saar, Maija P. Valta, Rosalie Nolley, Jennifer Santos and Donna M. Peehl

    Version of Record online : 18 NOV 2013, DOI: 10.1002/ijc.28579

  15. Global transition of human serum albumin to prefibrillar aggregates induced by temsirolimus: Insight into implications of anti-renal cancer drug

    Journal of Molecular Recognition

    Anas Shamsi, Azaj Ahmed and Bilqees Bano

    Version of Record online : 27 NOV 2017, DOI: 10.1002/jmr.2688

  16. You have free access to this content
    A dose-finding study of temsirolimus and liposomal doxorubicin for patients with recurrent and refractory bone and soft tissue sarcoma

    International Journal of Cancer

    Volume 133, Issue 4, 15 August 2013, Pages: 997–1005, K.A. Thornton, A.R. Chen, M.M. Trucco, P. Shah, B.A. Wilky, N. Gul, M.A. Carrera-Haro, M. Fogle Ferreira, U. Shafique, J.D. Powell, C.F. Meyer and D.M. Loeb

    Version of Record online : 4 MAR 2013, DOI: 10.1002/ijc.28083

  17. You have free access to this content
    Comparative Study of Rapamycin and Temsirolimus Demonstrates Superimposable Anti-Tumour Potency on Prostate Cancer Cells

    Basic & Clinical Pharmacology & Toxicology

    Volume 112, Issue 1, January 2013, Pages: 63–69, Paolo Fagone, Marco Donia, Katia Mangano, Cinzia Quattrocchi, Santa Mammana, Marinella Coco, Massimo Libra, James A. McCubrey and Ferdinando Nicoletti

    Version of Record online : 26 JUL 2012, DOI: 10.1111/j.1742-7843.2012.00923.x

  18. Targeted Therapies for Metastatic Renal Cell Carcinoma: An Overview of Toxicity and Dosing Strategies

    The Oncologist

    Volume 13, Issue 10, October 2008, Pages: 1084–1096, Thomas E. Hutson, Robert A. Figlin, John G. Kuhn and Robert J. Motzer

    Version of Record online : 6 OCT 2008, DOI: 10.1634/theoncologist.2008-0120

  19. You have free access to this content
    A dual-specific anti-IGF-1/IGF-2 human monoclonal antibody alone and in combination with temsirolimus for therapy of neuroblastoma

    International Journal of Cancer

    Volume 137, Issue 9, 1 November 2015, Pages: 2243–2252, Qi Zhao, Hoa Tran, Dimiter S. Dimitrov and Nai-Kong V. Cheung

    Version of Record online : 19 MAY 2015, DOI: 10.1002/ijc.29588

  20. You have free access to this content
    Temsirolimus combined with cisplatin or bevacizumab is active in osteosarcoma models

    International Journal of Cancer

    Volume 135, Issue 12, 15 December 2014, Pages: 2770–2782, Emmy D.G. Fleuren, Yvonne M.H. Versleijen-Jonkers, Melissa H.S. Roeffen, Gerben M. Franssen, Uta E. Flucke, Peter J. Houghton, Wim J.G. Oyen, Otto C. Boerman and Winette T.A. van der Graaf

    Version of Record online : 5 MAY 2014, DOI: 10.1002/ijc.28933